DrugTestKitUSA Author
About the Author
Dr. Awais is a Pharmacist and medical writer with specialized research experience. He has extensive knowledge in the fields of public health, pharmacology, medicine, pharmacotherapy, pharmacovigilance, ADR reporting, and drug testing.
He has experience in drug testing and sample analysis, working in a Drug Testing Laboratory during coursework, research and training.
Dr. Awais received his PharmD from Islamia University Bahawalpur in 2019. He graduated as a silver medalist and winner of the Department Pharma Academic Quiz Program in 2019.
As the resident medical writer at DrugTestKitUSA, Dr. Awais has written about many relevant topics. Please view his work for Drug Test Blog below.
FDA Approves First Test to Help Identify Elevated Risk of Opioid Use Disorder
The AvertD test is a prescription-only genetic test for those 18+ to assess the risk of opioid use disorder using a cheek swab.
Exploring Rehabs, Sober Living and the Role of Drug Tests
The path to recovery is unique for each individual. Rehabs, sober living homes and drug tests contribute to a comprehensive and successful recovery journey.
Emergency Use Authorization for Flowflex Plus COVID-19 & Flu A/B Combo Test
The Acon Laboratories Flowflex Plus COVID-19 and Flu A/B Home Test has received Emergency Use Authorization (EUA) from the FDA.
California Cannabis Laws Offer New Protections for Employee Use in 2024
California Cannabis Laws Offer New Protections for Employee Use. Learn how this impacts workplace drug testing policies.
FDA Approves First-Ever OTC Fentanyl Test for Consumer Use
The FDA has approved the first OTC fentanyl test, making it more accessible. This test empowers consumers to detect fentanyl, enhancing safety and awareness.
Tranq-dope: Deadly Fentanyl-Xylazine Mix
A dangerous mixture known as tranq-dope, a blend of fentanyl and xylazine, has emerged as a potent threat.